This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Maeda, Y.
Right arrow Articles by Makino, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maeda, Y.
Right arrow Articles by Makino, M.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, October 2009, p. 1399-1404, Vol. 16, No. 10
1071-412X/09/$08.00+0     doi:10.1128/CVI.00203-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Inhibition of the Multiplication of Mycobacterium leprae by Vaccination with a Recombinant M. bovis BCG Strain That Secretes Major Membrane Protein II in Mice {triangledown}

Y. Maeda, T. Tamura, M. Matsuoka, and M. Makino*

Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, 4-2-1 Aobacho, Higashimurayama, Tokyo 189-0002, Japan

Received 19 May 2009/ Returned for modification 10 June 2009/ Accepted 28 July 2009

The ability of a recombinant Mycobacterium bovis BCG strain that secretes major membrane protein II (MMP-II) of Mycobacterium leprae (BCG-SM) to confer protection against leprosy was evaluated by use of a mouse footpad model. C57BL/6J mice intradermally inoculated with BCG-SM produced splenic T cells which secreted significant amounts of gamma interferon (IFN-{gamma}) in response to either the recombinant MMP-II, the M. leprae-derived membrane fraction, or the BCG-derived cytosolic fraction in vitro more efficiently than those from the mice infected with the vector control BCG strain (BCG-pMV, a BCG strain containing pMV-261). A higher percentage of CD8+ T cells obtained from BCG-SM-inoculated mice than those obtained from BCG-pMV-inoculated mice produced intracellular IFN-{gamma} on restimulation with the M. leprae antigens. BCG-SM inhibited the multiplication of M. leprae in the footpads of C57BL/6J mice more efficiently than BCG-pMV. These results indicate that a BCG strain that secretes MMP-II could be a better vaccine candidate for leprosy.

* Corresponding author. Mailing address: Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, 4-2-1 Aobacho, Higashimurayama, Tokyo 189-0002, Japan. Phone: 81-42-391-8211. Fax: 81-42-391-8212. E-mail: mmaki{at}nih.go.jp

{triangledown} Published ahead of print on 12 August 2009.

Clinical and Vaccine Immunology, October 2009, p. 1399-1404, Vol. 16, No. 10
1071-412X/09/$08.00+0     doi:10.1128/CVI.00203-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»